VistaGen Deferred Long Term Liab from 2010 to 2024
| VTGN Stock | USD 4.50 0.09 2.04% |
Deferred Long Term Liabilities | First Reported 2011-06-30 | Previous Quarter 713.3 K | Current Value 723 K | Quarterly Volatility 666.5 K |
Check VistaGen Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among VistaGen main balance sheet or income statement drivers, such as Interest Expense of 25.1 K, Selling General Administrative of 12.5 M or Other Operating Expenses of 71.3 M, as well as many exotic indicators such as Dividend Yield of 1.0E-4, Average Payables of 0.0 or ROIC of 20.05. VistaGen financial statements analysis is a perfect complement when working with VistaGen Therapeutics Valuation or Volatility modules.
VistaGen | Deferred Long Term Liab |
Latest VistaGen Therapeutics' Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of VistaGen Therapeutics over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. VistaGen Therapeutics' Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in VistaGen Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
VistaGen Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 288,854 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 109.81 | |
| Mean Deviation | 268,544 | |
| Median | 139,200 | |
| Standard Deviation | 317,192 | |
| Sample Variance | 100.6B | |
| Range | 861.3K | |
| R-Value | 0.92 | |
| Mean Square Error | 17.2B | |
| R-Squared | 0.84 | |
| Slope | 65,038 | |
| Total Sum of Squares | 1.4T |
VistaGen Deferred Long Term Liab History
About VistaGen Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include VistaGen Therapeutics income statement, its balance sheet, and the statement of cash flows. VistaGen Therapeutics investors use historical funamental indicators, such as VistaGen Therapeutics's Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although VistaGen Therapeutics investors may use each financial statement separately, they are all related. The changes in VistaGen Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on VistaGen Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on VistaGen Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in VistaGen Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 820.3 K | 861.3 K |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards VistaGen Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, VistaGen Therapeutics' short interest history, or implied volatility extrapolated from VistaGen Therapeutics options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether VistaGen Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of VistaGen Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vistagen Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vistagen Therapeutics Stock:Check out the analysis of VistaGen Therapeutics Correlation against competitors. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.Note that the VistaGen Therapeutics information on this page should be used as a complementary analysis to other VistaGen Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for VistaGen Stock analysis
When running VistaGen Therapeutics' price analysis, check to measure VistaGen Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VistaGen Therapeutics is operating at the current time. Most of VistaGen Therapeutics' value examination focuses on studying past and present price action to predict the probability of VistaGen Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VistaGen Therapeutics' price. Additionally, you may evaluate how the addition of VistaGen Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is VistaGen Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share 0.077 | Quarterly Revenue Growth 1.291 | Return On Assets (0.26) | Return On Equity (0.45) |
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.